Viatris Inc. (VTRS)
NASDAQ: VTRS · Real-Time Price · USD
12.52
+0.39 (3.22%)
At close: Dec 20, 2024, 4:00 PM
12.40
-0.12 (-0.96%)
After-hours: Dec 20, 2024, 6:29 PM EST
Viatris Revenue
Viatris had revenue of $3.75B in the quarter ending September 30, 2024, a decrease of -4.84%. This brings the company's revenue in the last twelve months to $15.05B, down -2.70% year-over-year. In the year 2023, Viatris had annual revenue of $15.43B, down -5.14%.
Revenue (ttm)
$15.05B
Revenue Growth
-2.70%
P/S Ratio
0.99
Revenue / Employee
$396,013
Employees
38,000
Market Cap
14.94B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 15.43B | -835.80M | -5.14% |
| Dec 31, 2022 | 16.26B | -1.62B | -9.08% |
| Dec 31, 2021 | 17.89B | 5.94B | 49.73% |
| Dec 31, 2020 | 11.95B | 445.50M | 3.87% |
| Dec 31, 2019 | 11.50B | 66.60M | 0.58% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fresenius Medical Care AG | 21.46B |
| Baxter International | 15.06B |
| Avantor | 6.82B |
| Moderna | 5.08B |
| Hologic | 4.03B |
| Align Technology | 3.96B |
| United Therapeutics | 2.76B |
| Royalty Pharma | 2.27B |
VTRS News
- 3 days ago - Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology - PRNewsWire
- 19 days ago - Mapi Pharma is Seeking New Depot Product Partnerships - GlobeNewsWire
- 4 weeks ago - UK watchdog fines Viatris $1.9 mln over rule breach in Theramex probe - Reuters
- 4 weeks ago - Viatris Inc. (VTRS) Management Presents at Jefferies London Healthcare Conference (Transcript) - Seeking Alpha
- 5 weeks ago - Viatris Inc. (VTRS) UBS Global Healthcare Conference (Transcript) - Seeking Alpha
- 6 weeks ago - Bargain Priced Viatris Reports Strong Q3 Earnings Results - Seeking Alpha
- 6 weeks ago - Generic Drugmaker Viatris Beats Expectations In Q3, CEO Praises $2 Billion Debt Paydown - Benzinga
- 6 weeks ago - Viatris Inc. (VTRS) Q3 2024 Earnings Call Transcript - Seeking Alpha